FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2003222772> ?p ?o ?g. }

• W2003222772 endingPage "1017" @default.
• W2003222772 startingPage "1011" @default.
• W2003222772 abstract "Object. Findings from previous multicenter clinical trials have suggested that tirilazad mesylate, a synthetic nonhormonal 21-aminosteroid, might be effective in preventing delayed cerebral ischemia following subarachnoid hemorrhage (SAH). This beneficial effect, however, was greater in males than females, possibly because of gender-related pharmacokinetic differences. The authors sought to assess the effects of administering a larger dose of tirilazad in women with SAH. Methods. To test the efficacy of a higher tirilazad mesylate dose in female patients, a prospective randomized, doubleblind, vehicle-controlled trial was conducted at 56 neurosurgical centers in Europe, Australia, New Zealand, and South Africa. Eight hundred nineteen patients were randomly assigned to receive either 15 mg/kg/day of tirilazad mesylate or a placebo containing the citrate vehicle. The two groups were similar in prognostic factors for delayed cerebral ischemia and overall outcome. High-dose tirilazad appeared to be well tolerated because no differences in the incidence of untoward medical events were noted between the two groups. Medical and surgical interventions were no different in the two treatment groups except for hyperdynamic therapy (intentional hypervolemia, induced hypertension, and/or hemodilution), which was more often used in the placebo-treated group to counteract symptomatic vasospasm (24% of patients given placebo compared with 18% of patients given tirilazad, p = 0.02). Mortality rates and overall outcome, assessed using the Glasgow Outcome Scale at 3 months post-SAH, were not different between the two groups, despite a significantly lower incidence of delayed cerebral ischemia in patients given tirilazad. Post hoc subgroup analysis by neurological grade also did not reveal significant differences in outcome, although a trend toward a lower mortality rate favoring the study drug was present in patients with neurological Grade IV and V at admission (32% compared with 37%). Symptomatic vasospasm occurred in 33.7% of the placebo-treated patients as opposed to 24.8% of the patients who were given tirilazad (p = 0.005). The severity of symptomatic vasospasm was also attenuated by administration of the study drug (severe symptomatic vasospasm was reported in 11% of the placebo-treated patients compared with 6% of patients in the tirilazad-treated group (p = 0.008). Clinical cerebral infarction from vasospasm was also reduced from 13% in the vehicle-treated group to 8% in the tirilazad-treated group (p < 0.04). Conclusions. The authors conclude that high-dose tirilazad mesylate is well tolerated in women with aneurysmal SAH. Although a significant reduction in the incidence of symptomatic vasospasm was observed in the treatment group, the primary end point (mortality rate at 3 months post-SAH) was not affected by the study drug. The use of other potentially effective rescue therapies (that is, hypervolemia, hemodilution, and induced hypertension) to counteract vasospasm may have been responsible for these contrasting observations between the two groups." @default.
• W2003222772 created "2016-06-24" @default.
• W2003222772 creator A5000886350 @default.
• W2003222772 creator A5002392572 @default.
• W2003222772 creator A5017365860 @default.
• W2003222772 creator A5036168850 @default.
• W2003222772 creator A5060322626 @default.
• W2003222772 creator A5061401811 @default.
• W2003222772 creator A5070250547 @default.
• W2003222772 creator A5074963669 @default.
• W2003222772 creator A5078044974 @default.
• W2003222772 date "1999-06-01" @default.
• W2003222772 modified "2023-10-01" @default.
• W2003222772 title "Double-blind, randomized, vehicle-controlled study of high-dose tirilazad mesylate in women with aneurysmal subarachnoid hemorrhage. Part I. A cooperative study in Europe, Australia, New Zealand, and South Africa" @default.
• W2003222772 cites W1527947633 @default.
• W2003222772 cites W1605672252 @default.
• W2003222772 cites W1617537169 @default.
• W2003222772 cites W1965925619 @default.
• W2003222772 cites W1978709862 @default.
• W2003222772 cites W1989734551 @default.
• W2003222772 cites W1990082069 @default.
• W2003222772 cites W2003546423 @default.
• W2003222772 cites W2004613789 @default.
• W2003222772 cites W2008885202 @default.
• W2003222772 cites W2020790632 @default.
• W2003222772 cites W2024016745 @default.
• W2003222772 cites W2027123157 @default.
• W2003222772 cites W2040589741 @default.
• W2003222772 cites W2065094515 @default.
• W2003222772 cites W2071354717 @default.
• W2003222772 cites W2078080170 @default.
• W2003222772 cites W2091949588 @default.
• W2003222772 cites W2098798964 @default.
• W2003222772 cites W2170038628 @default.
• W2003222772 cites W37191436 @default.
• W2003222772 cites W4246289305 @default.
• W2003222772 cites W4255876153 @default.
• W2003222772 cites W4376595524 @default.
• W2003222772 doi "https://doi.org/10.3171/jns.1999.90.6.1011" @default.
• W2003222772 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10350245" @default.
• W2003222772 hasPublicationYear "1999" @default.
• W2003222772 type Work @default.
• W2003222772 sameAs 2003222772 @default.
• W2003222772 citedByCount "171" @default.
• W2003222772 countsByYear W20032227722012 @default.
• W2003222772 countsByYear W20032227722013 @default.
• W2003222772 countsByYear W20032227722014 @default.
• W2003222772 countsByYear W20032227722015 @default.
• W2003222772 countsByYear W20032227722016 @default.
• W2003222772 countsByYear W20032227722017 @default.
• W2003222772 countsByYear W20032227722018 @default.
• W2003222772 countsByYear W20032227722019 @default.
• W2003222772 countsByYear W20032227722020 @default.
• W2003222772 countsByYear W20032227722021 @default.
• W2003222772 countsByYear W20032227722022 @default.
• W2003222772 crossrefType "journal-article" @default.
• W2003222772 hasAuthorship W2003222772A5000886350 @default.
• W2003222772 hasAuthorship W2003222772A5002392572 @default.
• W2003222772 hasAuthorship W2003222772A5017365860 @default.
• W2003222772 hasAuthorship W2003222772A5036168850 @default.
• W2003222772 hasAuthorship W2003222772A5060322626 @default.
• W2003222772 hasAuthorship W2003222772A5061401811 @default.
• W2003222772 hasAuthorship W2003222772A5070250547 @default.
• W2003222772 hasAuthorship W2003222772A5074963669 @default.
• W2003222772 hasAuthorship W2003222772A5078044974 @default.
• W2003222772 hasConcept C141071460 @default.
• W2003222772 hasConcept C142724271 @default.
• W2003222772 hasConcept C168563851 @default.
• W2003222772 hasConcept C17624336 @default.
• W2003222772 hasConcept C204787440 @default.
• W2003222772 hasConcept C27081682 @default.
• W2003222772 hasConcept C2776820941 @default.
• W2003222772 hasConcept C2777736543 @default.
• W2003222772 hasConcept C2777796830 @default.
• W2003222772 hasConcept C2778506911 @default.
• W2003222772 hasConcept C42219234 @default.
• W2003222772 hasConcept C71924100 @default.
• W2003222772 hasConceptScore W2003222772C141071460 @default.
• W2003222772 hasConceptScore W2003222772C142724271 @default.
• W2003222772 hasConceptScore W2003222772C168563851 @default.
• W2003222772 hasConceptScore W2003222772C17624336 @default.
• W2003222772 hasConceptScore W2003222772C204787440 @default.
• W2003222772 hasConceptScore W2003222772C27081682 @default.
• W2003222772 hasConceptScore W2003222772C2776820941 @default.
• W2003222772 hasConceptScore W2003222772C2777736543 @default.
• W2003222772 hasConceptScore W2003222772C2777796830 @default.
• W2003222772 hasConceptScore W2003222772C2778506911 @default.
• W2003222772 hasConceptScore W2003222772C42219234 @default.
• W2003222772 hasConceptScore W2003222772C71924100 @default.
• W2003222772 hasIssue "6" @default.
• W2003222772 hasLocation W20032227721 @default.
• W2003222772 hasLocation W20032227722 @default.
• W2003222772 hasOpenAccess W2003222772 @default.
• W2003222772 hasPrimaryLocation W20032227721 @default.
• W2003222772 hasRelatedWork W1988742580 @default.
• W2003222772 hasRelatedWork W2013269907 @default.
• W2003222772 hasRelatedWork W2028637529 @default.
• W2003222772 hasRelatedWork W2039711219 @default.

• next